MedPath

Retrospective Record-review Study in Patients Who Had Diabetic Foot Ulcer

Conditions
Diabetic Foot Ulcer
Interventions
Registration Number
NCT05135130
Lead Sponsor
Oneness Biotech Co., Ltd.
Brief Summary

The purpose of the study is to evaluate the medical cost of illness for DFUs on the patients who had used ON101 or Aquacel® in the ON101CLCT02 trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
176
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
ON101 CreamON101 CreamPatients Who Had Participated in the ON101CLCT02 Diabetic Foot Ulcer Trial and assigned to ON101 Cream arm
Primary Outcome Measures
NameTimeMethod
Wound characteristics of DFUs (classification and proportion)Up to two years after the patient had completed or early withdrawn from the ON101CLCT02 trial
Proportion of DFU recurrence after completing or withdrawing from the ON101CLCT02 trialUp to two years after the patient had completed or early withdrawn from the ON101CLCT02 trial
Medical costs due to DFUsUp to two years after the patient had completed or early withdrawn from the ON101CLCT02 trial
Demographic characteristicsUp to two years after the patient had completed or early withdrawn from the ON101CLCT02 trial
Proportion of wound infection, gangrene, and amputationUp to two years after the patient had completed or early withdrawn from the ON101CLCT02 trial
Frequency of wound infection, gangrene, and amputationUp to two years after the patient had completed or early withdrawn from the ON101CLCT02 trial
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

China Medical University Hospital

🇨🇳

Taichung City, Taiwan

© Copyright 2025. All Rights Reserved by MedPath